GLA and Fabry disease: Treatment for FD includes ERT, utilizing agalsidase alfa and beta, which are distinct medications composed of recombined proteins employed in ERT, a therapeutic approach aiming to introduce the deficient enzyme into the patient’s system [1,30,31].